Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 1
2014 2
2016 10
2017 4
2018 6
2019 8
2020 2
2021 5
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Herrera FG, Ronet C, Ochoa de Olza M, Barras D, Crespo I, Andreatta M, Corria-Osorio J, Spill A, Benedetti F, Genolet R, Orcurto A, Imbimbo M, Ghisoni E, Navarro Rodrigo B, Berthold DR, Sarivalasis A, Zaman K, Duran R, Dromain C, Prior J, Schaefer N, Bourhis J, Dimopoulou G, Tsourti Z, Messemaker M, Smith T, Warren SE, Foukas P, Rusakiewicz S, Pittet MJ, Zimmermann S, Sempoux C, Dafni U, Harari A, Kandalaft LE, Carmona SJ, Dangaj Laniti D, Irving M, Coukos G. Herrera FG, et al. Among authors: imbimbo m. Cancer Discov. 2022 Jan;12(1):108-133. doi: 10.1158/2159-8290.CD-21-0003. Epub 2021 Sep 3. Cancer Discov. 2022. PMID: 34479871 Free PMC article.
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma.
Barras D, Ghisoni E, Chiffelle J, Orcurto A, Dagher J, Fahr N, Benedetti F, Crespo I, Grimm AJ, Morotti M, Zimmermann S, Duran R, Imbimbo M, de Olza MO, Navarro B, Homicsko K, Bobisse S, Labes D, Tsourti Z, Andriakopoulou C, Herrera F, Pétremand R, Dummer R, Berthod G, Kraemer AI, Huber F, Thevenet J, Bassani-Sternberg M, Schaefer N, Prior JO, Matter M, Aedo V, Dromain C, Corria-Osorio J, Tissot S, Kandalaft LE, Gottardo R, Pittet M, Sempoux C, Michielin O, Dafni U, Trueb L, Harari A, Laniti DD, Coukos G. Barras D, et al. Among authors: imbimbo m. Sci Immunol. 2024 Feb 2;9(92):eadg7995. doi: 10.1126/sciimmunol.adg7995. Epub 2024 Feb 2. Sci Immunol. 2024. PMID: 38306416
Cellular Therapy in NSCLC: Between Myth and Reality.
Imbimbo M, Wetterwald L, Friedlaender A, Parikh K, Addeo A. Imbimbo M, et al. Curr Oncol Rep. 2023 Oct;25(10):1161-1174. doi: 10.1007/s11912-023-01443-z. Epub 2023 Aug 30. Curr Oncol Rep. 2023. PMID: 37646900 Free PMC article. Review.
Cell therapies in ovarian cancer.
Sarivalasis A, Morotti M, Mulvey A, Imbimbo M, Coukos G. Sarivalasis A, et al. Among authors: imbimbo m. Ther Adv Med Oncol. 2021 Apr 22;13:17588359211008399. doi: 10.1177/17588359211008399. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33995591 Free PMC article. Review.
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V. Ferrara R, et al. Among authors: imbimbo m. Cochrane Database Syst Rev. 2021 Apr 30;4(4):CD013257. doi: 10.1002/14651858.CD013257.pub3. Cochrane Database Syst Rev. 2021. PMID: 33930176 Free PMC article.
Ovarian Cancer Immunotherapy: Turning up the Heat.
Ghisoni E, Imbimbo M, Zimmermann S, Valabrega G. Ghisoni E, et al. Among authors: imbimbo m. Int J Mol Sci. 2019 Jun 15;20(12):2927. doi: 10.3390/ijms20122927. Int J Mol Sci. 2019. PMID: 31208030 Free PMC article. Review.
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines.
Proto C, Manglaviti S, Lo Russo G, Musca M, Galli G, Imbimbo M, Perrino M, Cordua N, Rulli E, Ballatore Z, Maso AD, Chella A, Sbrana A, Prelaj A, Ferrara R, Occhipinti M, Brambilla M, De Toma A, Mazzeo L, Beninato T, Signorelli D, Massa G, Greco FG, Calareso G, Miliziano D, Di Mauro RM, Mella G, Lucarelli A, Paggio A, Galli F, Torri V, de Braud FGM, Pasello G, Petrini I, Berardi R, Ganzinelli M, Garassino MC, Zucali PA. Proto C, et al. Among authors: imbimbo m. J Thorac Oncol. 2023 Aug;18(8):1070-1081. doi: 10.1016/j.jtho.2023.04.009. Epub 2023 Apr 23. J Thorac Oncol. 2023. PMID: 37094664 Clinical Trial.
Cognitive impairment and chemotherapy: a brief overview.
Vitali M, Ripamonti CI, Roila F, Proto C, Signorelli D, Imbimbo M, Corrao G, Brissa A, Rosaria G, de Braud F, Garassino MC, Lo Russo G. Vitali M, et al. Among authors: imbimbo m. Crit Rev Oncol Hematol. 2017 Oct;118:7-14. doi: 10.1016/j.critrevonc.2017.08.001. Epub 2017 Aug 14. Crit Rev Oncol Hematol. 2017. PMID: 28917271 Review.
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V. Ferrara R, et al. Among authors: imbimbo m. Cochrane Database Syst Rev. 2020 Dec 14;12(12):CD013257. doi: 10.1002/14651858.CD013257.pub2. Cochrane Database Syst Rev. 2020. PMID: 33316104 Free PMC article. Updated.
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
Drew Y, Kim JW, Penson RT, O'Malley DM, Parkinson C, Roxburgh P, Plummer R, Im SA, Imbimbo M, Ferguson M, Rosengarten O, Steeghs N, Kim MH, Gal-Yam E, Tsoref D, Kim JH, You B, De Jonge M, Lalisang R, Gort E, Bastian S, Meyer K, Feeney L, Baker N, Ah-See ML, Domchek SM, Banerjee S; MEDIOLA Investigators. Drew Y, et al. Among authors: imbimbo m. Clin Cancer Res. 2024 Jan 5;30(1):50-62. doi: 10.1158/1078-0432.CCR-23-2249. Clin Cancer Res. 2024. PMID: 37939124 Free PMC article. Clinical Trial.
42 results